Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
25.09. | Nuvectis Pharma, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
11.08. | Nuvectis Pharma, Inc.: Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900 | 424 | GlobeNewswire (Europe) | The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combination... ► Artikel lesen | |
05.08. | Nuvectis Pharma, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
NUVECTIS PHARMA Aktie jetzt für 0€ handeln | |||||
05.08. | Nuvectis Pharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
05.08. | Nuvectis Pharma GAAP EPS of -$0.30 | 3 | Seeking Alpha | ||
05.08. | Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights | 232 | GlobeNewswire (Europe) | NXP900 becomes the lead drug candidate after successfully completing the Phase 1a dose escalation study in patients with advanced solid tumors and a drug-drug interaction study in healthy volunteers... ► Artikel lesen | |
04.08. | Nuvectis Pharma stock price target lowered to $10 at H.C. Wainwright | 1 | Investing.com | ||
31.07. | Nuvectis axes ovarian cancer program after seeing phase 1b data | 2 | FierceBiotech | ||
31.07. | Nuvectis halts NXP800 development for ovarian cancer, shifts focus | 2 | Investing.com | ||
31.07. | Nuvectis Pharma, Inc.: Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study | 143 | GlobeNewswire (Europe) | Available data from 13 patients with recurrent, platinum resistant, ARID1a-mutated ovarian cancer treated with 75 mg/day in the NXP800 Phase 1b study includes 2 partial responses and 3 stable diseases... ► Artikel lesen | |
08.07. | Nuvectis reports positive drug interaction study for cancer drug NXP900 | 1 | Investing.com | ||
13.06. | Nuvectis Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
06.05. | Nuvectis Pharma, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
06.05. | Nuvectis Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
06.05. | Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights | 123 | GlobeNewswire (Europe) | NXP900 clinical data presentation from the Phase 1a dose escalation study at the 2025 American Association for Cancer Research (AACR) conference demonstrated robust pharmacodynamic response and acceptable... ► Artikel lesen | |
30.04. | Why Nuvectis Pharma, Inc. (NVCT) is Surging in 2025 | 1 | Insider Monkey | ||
29.04. | Nuvectis Pharma, Inc.: Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting | 1 | GlobeNewswire (USA) | ||
05.11.24 | Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights | 201 | GlobeNewswire (Europe) | Clinical data update from the NXP800 Phase 1b study expected this month; NXP800 granted Orphan Drug Designation for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal... ► Artikel lesen | |
28.10.24 | PESG Research: PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update | 313 | Business Wire | Nuvectis Pharma (NASDAQ: NVCT) continues to make strides in precision oncology, gaining momentum following presentations last week at the AACR-NCI-EORTC Symposium where its drug candidate NXP900... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
RECURSION PHARMACEUTICALS | 5,520 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
TAYSHA GENE THERAPIES | 4,880 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome | Breakthrough Therapy designation granted based on FDA's review of available clinical evidence of safety and efficacy from all 12 patients treated in Part A of the REVEAL Phase 1/2 trials Finalized... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 44,180 | +2,74 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 7,460 | 0,00 % | Aktien Europa: Leichte Gewinne zum Wochenauftakt | AMSTERDAM/LONDON/PARIS/ZÜRICH (dpa-AFX) - Europas wichtigste Aktienmärkte starten am Montag zunächst freundlich in die neue Woche. Allerdings blieb die Risikobereitschaft verhalten angesichts der bleiben... ► Artikel lesen | |
VERA THERAPEUTICS | 29,190 | +1,39 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 4, 2025, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen | |
STRUCTURE THERAPEUTICS | 26,620 | +2,23 % | Aktien New York: Weitere Rekorde - auch dank Nvidia und Apple | NEW YORK (dpa-AFX) - Die US-Börsen haben am Montag nach einem verhaltenen Start ihre Rekordjagd fortgesetzt. Auch dank deutlicher Kursgewinne der Schwergewichte Nvidia und Apple verzeichnete der Leitindex... ► Artikel lesen | |
KINIKSA PHARMACEUTICALS | 37,470 | 0,00 % | What Analysts Are Saying About Kiniksa Pharmaceuticals Stock | ||
APOGEE THERAPEUTICS | 39,610 | 0,00 % | Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 ... | SAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for... ► Artikel lesen | |
DISC MEDICINE | 65,86 | -1,86 % | Disc Medicine Inc: Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP) | Disc is seeking accelerated approval and priority review of its NDA submissionFDA decision to accept and file the NDA for review occurs within 60 days of submission WATERTOWN, Mass., Sept. 30,... ► Artikel lesen | |
TANGO THERAPEUTICS | 7,690 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights | - First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors - - First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative PRMT5... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 21,250 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025 | ||
SUMMIT THERAPEUTICS | 20,870 | 0,00 % | Summit Therapeutics: HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025 | Ivonescimab in Combination with Chemotherapy in HARMONi-6, Conducted by Akeso in China, is the First Known Regimen to Achieve a Statistically Significant Clinically Meaningful Improvement in PFS... ► Artikel lesen | |
MINERALYS THERAPEUTICS | 40,450 | +1,61 % | Mineralys auf Stifel-Forum: Strategischer Fahrplan für Blutdruckmittel Lorundrostat | ||
PHATHOM PHARMACEUTICALS | 11,820 | -3,82 % | Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
SOLID BIOSCIENCES | 5,740 | 0,00 % | Solid Biosciences Inc.: Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CHARLESTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac... ► Artikel lesen |